On August 21, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, reported a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Press release, Mirati, AUG 21, 2023, View Source [SID1234634604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Findings will be presented at the 2023 World Conference on Lung Cancer during the press conference on September 10th 10:35 a.m. – 10:40 a.m. SGT / September 9th 7:35 p.m. – 7:40 p.m. PT and as a mini-oral presentation in the "Targeted Therapy: KRAS and Beyond" session occurring on September 10th at 4:22 p.m. SGT / 1:22 a.m. PT.